𝔖 Bobbio Scriptorium

✦ LIBER ✦

Tasocitinib (CP-690,550), an oral Janus kinase inhibitor, consistently improves the clinical signs of moderate to severe psoriasis in different body regions

Book ID: 116587667
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 45 KB
Volume: 64
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2010.09.624

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tasocitinib (CP-690,550), an oral Janus

Tasocitinib (CP-690,550), an oral Janus kinase inhibitor, significantly improves the symptoms of moderate to severe psoriasis with early onset of efficacy

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 48 KB

An evaluation of the effect of tasocitin

An evaluation of the effect of tasocitinib (CP-690,550), an oral Janus kinase inhibitor, on pruritus in patients with plaque psoriasis

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 45 KB

The itch severity item: Mediation modeli

The itch severity item: Mediation modeling and measurement characteristics from a phase IIb trial of tasocitinib (CP-690,550), an oral Janus kinase inhibitor, in patients with plaque psoriasis

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Tofacitinib (CP-690,550), an oral Janus

Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis

✍ Mamolo, C.; Harness, J.; Tan, H.; Menter, A. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB